Payment overview · 2025
General Payments
$7,624.96
145 reported records · 27 companies
Healthcare provider profile · identity verified
Alam N Khan, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · LONDON, KY · NPI 1629047162
Verified facts
What the public records show
CMS Open Payments records show Alam N Khan, MD received $7,624.96 in general payments during 2025 across 145 reported records.
ABBVIE INC. accounted for 77.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Briviact, Nurtec Odt, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nuplazid by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Nurtec Odt by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $5,869.68 | 77.0% | 53 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $203.65 | 2.7% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $181.18 | 2.4% | 10 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $154.08 | 2.0% | 9 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $136.00 | 1.8% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $118.29 | 1.6% | 6 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $109.88 | 1.4% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $81.43 | 1.1% | 5 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $77.63 | 1.0% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $76.74 | 1.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.63 | 1.0% | 5 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $68.46 | 0.9% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $68.29 | 0.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.74 | 0.8% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $45.86 | 0.6% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $45.26 | 0.6% | 2 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $37.56 | 0.5% | 2 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.96 | 0.5% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $32.98 | 0.4% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $24.60 | 0.3% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $21.43 | 0.3% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.87 | 0.3% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $18.48 | 0.2% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $16.70 | 0.2% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $16.38 | 0.2% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $15.61 | 0.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.59 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,250.00 | 2 |
| Food and Beverage | $2,275.96 | 142 |
| Education | $99.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $5,717.27 | 42 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $263.18 | 28 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $225.22 | 17 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $181.18 | 10 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $154.08 | 9 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $140.57 | 7 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $118.29 | 6 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $109.88 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $81.43 | 5 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $76.74 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $74.63 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $74.63 | 5 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $68.46 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $68.29 | 4 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $60.74 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $60.74 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $45.86 | 3 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $37.56 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $37.00 | 2 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $33.96 | 2 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $33.38 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $32.98 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $32.90 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $11.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 36 | exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 62 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
36 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1348 | 212 |
| Clonazepam | Clonazepam | 363 | 52 |
| Diazepam | Diazepam | 361 | 52 |
| Alprazolam | Alprazolam | 300 | 42 |
| Levetiracetam | Levetiracetam | 263 | 68 |
| Tramadol Hcl | Tramadol Hcl | 253 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 249 | 53 |
| Primidone | Primidone | 241 | 53 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 227 | 54 |
| Pregabalin | Pregabalin | 223 | 34 |
| Topiramate | Topiramate | 182 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 176 | 40 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 174 | 29 |
| Donepezil Hcl Odt | Donepezil Hcl | 156 | 40 |
| Lacosamide | Lacosamide | 156 | 26 |
| Lamotrigine | Lamotrigine | 156 | 30 |
| Donepezil Hcl | Donepezil Hcl | 154 | 46 |
| Memantine Hcl | Memantine Hcl | 147 | 38 |
| Dalfampridine Er | Dalfampridine | 133 | 22 |
| Propranolol Hcl | Propranolol Hcl | 117 | 27 |
| Lorazepam | Lorazepam | 108 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 106 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 99 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 84 | 23 |
| Aptiom | Eslicarbazepine Acetate | 79 | 11 |
| Modafinil | Modafinil | 77 | 13 |
| Divalproex Sodium | Divalproex Sodium | 75 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 74 | 18 |
| Phenobarbital | Phenobarbital | 73 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 73 | 15 |
| Rizatriptan | Rizatriptan Benzoate | 72 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 14 |
| Kesimpta Pen | Ofatumumab | 71 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 71 | 20 |
| Trazodone Hcl | Trazodone Hcl | 71 | 21 |
| Baclofen | Baclofen | 69 | 21 |
| Nurtec Odt | Rimegepant Sulfate | 62 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 55 | 12 |
| Prednisone | Prednisone | 54 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 14 |
| Meclizine Hcl | Meclizine Hcl | 52 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | suppressed |
| Ubrelvy | Ubrogepant | 48 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 46 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 45 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | 18 |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 43 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 41 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | 12 |
| Aubagio | Teriflunomide | 40 | suppressed |
| Briviact | Brivaracetam | 40 | suppressed |
| Carbamazepine | Carbamazepine | 38 | suppressed |
| Amantadine | Amantadine Hcl | 37 | suppressed |
| Qulipta | Atogepant | 37 | suppressed |
| Botox | Onabotulinumtoxina | 36 | 13 |
| Clobazam | Clobazam | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Valtoco | Diazepam | 33 | 12 |
| Entacapone | Entacapone | 32 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 32 | 13 |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 30 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 30 | suppressed |
| Trokendi Xr | Topiramate | 30 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Rivastigmine | Rivastigmine | 28 | suppressed |
| Teriflunomide | Teriflunomide | 28 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 27 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 24 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 22 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 20 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Glatopa | Glatiramer Acetate | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Losartan Potassium | Losartan Potassium | 15 | suppressed |
| Vimpat | Lacosamide | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Gilenya | Fingolimod Hcl | 14 | suppressed |
| Lisinopril | Lisinopril | 14 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 14 | suppressed |
| Armodafinil | Armodafinil | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Xcopri | Cenobamate | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 11 | suppressed |
| Betaseron | Interferon Beta-1b | 11 | suppressed |
| Furosemide | Furosemide | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,624.96 · 145 records | ABBVIE INC. | AMYVID, AUSTEDO XR, BOTOX, BRIUMVI, Briviact, DAYBUE, Dysport, EPIDIOLEX, Fintepla, Gamunex-C, Gocovri, HYQVIA, Hizentra, KESIMPTA, KISUNLA, Leqembi, Motpoly XR, NURTEC ODT, Ocrevus Zunovo, PONVORY, QULIPTA, Rystiggo, SKYCLARYS, Senza, UBRELVY, ULTOMIRIS, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VYALEV, VYEPTI, VYVGART, ZAVZPRET, ZEPOSIA, Zilbrysq | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error